Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Beginning Cash Balance: 2012-2018

  • Niagen Bioscience's Beginning Cash Balance rose 2664.25% to $45.4 million in Q1 2018 from the same period last year, while for Mar 2018 it was $52.6 million, marking a year-over-year increase of 546.61%. This contributed to the annual value of $420,152 for FY2012, which is 81.13% down from last year.
  • According to the latest figures from Q1 2018, Niagen Bioscience's Beginning Cash Balance is $45.4 million, which was up 10,580,086.48% from $429 recorded in Q3 2017.
  • Over the past 5 years, Niagen Bioscience's Beginning Cash Balance peaked at $45.4 million during Q1 2018, and registered a low of $429 during Q3 2017.
  • In the last 3 years, Niagen Bioscience's Beginning Cash Balance had a median value of $3.6 million in 2016 and averaged $13.1 million.
  • As far as peak fluctuations go, Niagen Bioscience's Beginning Cash Balance crashed by 70.41% in 2017, and later soared by 2,664.25% in 2018.
  • Quarterly analysis of 3 years shows Niagen Bioscience's Beginning Cash Balance stood at $5.5 million in 2016, then plummeted by 70.41% to $429 in 2017, then soared by 2,664.25% to $45.4 million in 2018.
  • Its Beginning Cash Balance stands at $45.4 million for Q1 2018, versus $429 for Q3 2017 and $1.6 million for Q2 2017.